Nestlé India has rejected the non-compliance concerns raised by the Food Safety and Standards Authority of India (FSSAI) regarding its infant nutrition products, stating that NAN Excella Pro and Lactogen Pro comply with applicable regulations and that their labels were approved by an FSSAI expert committee.
The company’s response follows FSSAI’s initiation of three separate adjudication cases against Nestlé India concerning three infant nutrition products. Two cases relate to promotional and labelling claims involving NAN Excella Pro Stage 1 and Lactogen Pro 1, while the third concerns the biotin content of a sample of Nestlé’s follow-up formula.
For NAN Excella Pro Stage 1, FSSAI flagged claims relating to “5 HMOs” and “Whey Protein” in promotional material examined on e-commerce platforms. In the case of Lactogen Pro 1, the regulator raised concerns about a claim describing its whey protein as “easy to digest.”
According to FSSAI, the promotional claims were considered contrary to Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, which places restrictions on promotional material intended to increase the saleability of infant foods.
The third case relates to a laboratory finding involving a follow-up formula manufactured by Nestlé India. FSSAI said the sample was found to have biotin below the prescribed level during laboratory analysis, and a subsequent referral laboratory test also found the sample did not conform to the required biotin standard.
Nestlé India has disputed the regulatory concerns. A company spokesperson said the products and their labels had been approved by an FSSAI expert committee and that the company had submitted a detailed response to the authorities concerning the statements appearing on the labels. Nestlé said these statements were factual and supported by scientific literature.
The company has also reiterated its adherence to applicable regulations and said it would continue working with FSSAI. The adjudication proceedings will determine how the regulator’s concerns are addressed; the initiation of the cases does not by itself represent a final determination of liability.
The development highlights the regulatory scrutiny surrounding infant nutrition products, where product composition, labelling and promotional communication are subject to specific requirements. For dairy and infant-nutrition manufacturers, the case also underlines the importance of maintaining alignment between approved labels, promotional claims, scientific substantiation and regulatory requirements.
Source: Dairynews7x7 20 Sep, 2026 Read full story here
#DairyIndustry #InfantNutrition #FoodSafety #FSSAI #NestleIndia #DairyNews7x7
